Exclusive Summary

• Famotidine Injection, an off-patent H2 receptor antagonist, addresses a widespread global clinical need for treating peptic ulcers and GERD.
• The product has passed China's consistency evaluation, ensuring quality standards, and offers significant cost advantages over originator drugs, making it suitable for global distribution.
• Its inclusion in the WHO Essential Medicines List and recommendation by guidelines as an important auxiliary treatment for serious gastrointestinal conditions ensures market access and application in most regions.
• Despite the overall decline in the H2 blocker market, the injectable form maintains a rigid demand in acute, severe, or NPO patients, securing its niche market position.
• The manufacturer's strong foundation in injectable drug production and regulatory experience in China will facilitate faster registration and market entry in multiple countries globally.

Asset Materials

Contact Us for Full Materials